Background This study investigated the results of transanal total mesorectal excision (TaTME) combined with laparoscopy for locally advanced mid–low rectal cancer. Methods Patients with mid–low locally advanced rectal cancer (T3 category or above and/or N+) who underwent rectal resection with TaTME technique were enrolled prospectively. Patients who had distant metastasis, multiple malignancies, intestinal obstruction or perforation, or a clinical complete response to chemoradiotherapy were excluded. Postoperative results, including morbidity, circumferential resection margin (CRM) assessment, short‐term survival and functional outcomes, were analysed. Results Thirty‐eight patients, with 25 mid and 13 low rectal tumours, who had elective resection by TaTME from March 2015 to September 2018 were included. There were 25 men and 13 women. Mean(s.d.) age was 58·2(16·4) years and mean(s.d.) BMI was 24·2(2·5) kg/m2. Tumours were 3–9 cm from the anal verge. Mean(s.d.) duration of surgery was 210(42) min. All patients had hand‐sewn anastomoses and protective ileostomies. There were no conversions, abdominal perineal resections or postoperative deaths. Four patients had a complication, including three presacral abscesses, all managed by transanastomotic drainage. At 3 months after ileostomy closure, all patients had perfect continence. Apart from a greater tumour diameter in patients with low rectal cancers (6·0 cm versus 4·6 cm in those with mid rectal tumours; P = 0·035), clinical features were similar in the two groups. CRM positivity was greater for low than for mid rectal tumours (3 of 13 versus 0 of 25 respectively; P = 0·034), and more patients with a low tumour had TME grade 2 (4 of 13 versus 1 of 25; P = 0·038). There was no difference in oncological outcomes at 17 months. Conclusion Although this study cohort was small, special attention should be paid to bulky low rectal tumours to reduce the rate of CRM positivity.
Objectives: evaluation of feasibility, safety, and outcomes of single port laparoscopic surgery (SPLS) for right hemicolectomy. Method and material: Prospective study of 84 patients suffering from right colon cancer who underwent SPLS between Decem-ber 2010 and December 2016 and were followed up until December 2017 in Hue Central Hospital. Results: Mean age of patients was 56.3 ±16.2 (25-87) years, fifty-five (64,28%) were males. Mean BMI was 24.2±5.3kg/m2. mean ASA score for all patients was 2.7 (1-3). Ten cases (11.9%) required additional ports in which 6 were finally converted to open surgery. There were no deaths as well as intraoperative complications. Mean tumor size was 4.4±3.6 (3-8 cm). For successful operated group with SPLS, mean operation time was 135.5±23.2 minutes. Blood loss was 54±22 ml. Mean incisional length (including extension for extraction) was 4.6±3.5cm. Mean lymph nodes harvest was 14.2±0.8. Stage I: 13.5%; stage II: 35.1%; stage III: 51.4%; Postoperative pain was 4 points at day 0. The surgical site infection rate was 2.7%. Mean hospital stay was 6.3±3.4 days. There was one anastomotic leakage in open conversion group. Mean follow-up period was 41.5 months (12-84 months). There were 7 local recurrences, 4 patients developed liver metastasis and 1 lung metastasis. The overall survival time of all stages was 96.2% (24 months); 92.8% (36 months) and 75.7% (60 months). Conclusion: SPLS for right hemicolectomy is feasible and safe. The cosmetic value is better (short incision confounded by um-bilicus). Other outcomes were equivalent to conventional laparoscopy.
We conducted a prospective, nonrandomized, observational study in Hue central hospital, which is one of the biggest hospitals in Vietnam, from January 2016 to January 2021. The hospital ethics committee approved the study protocol and all modifications during the study. The written informed consent was obtained from all pa-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.